Oculus Innovative Sciences (OCLS) Misses Q1 EPS by 5c

Oculus Innovative Sciences (NASDAQ: OCLS) reported Q1 EPS of ($0.15), $0.05 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $3.7 million versus the consensus estimate of $3.96 million.

"In late 2014, after making a strategic decision to enter the dermatology market directly, we deployed a direct U.S. sales force and launched four prescription dermatology products. We are pleased to see that the benefits of expanding our presence in the dermatology market, with its strong pricing reimbursement and quick sales ramps, has resulted in significant sales growth in the United States over the last six months," said Oculus' CEO Jim Schutz. "We believe the growth in dermatology sales will continue as we launch new products, grow our existing product lines and hire additional sales people."

For earnings history and earnings-related data on Oculus Innovative Sciences (OCLS) click here.

You May Also Be Interested In

• Nuvve Holding (NVVE) Reports Q1 Update
• Alphabet (GOOGL) CEO: Launching AI overviews in search across US this week; Gemini used by 1.5M+ developers
• Immucell Corp (ICCC) Reports Q1 Loss of $0.06